VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant testing methods across its oncology research programs, a strategic shift that could improve the predictive value of preclinical data and reduce reliance on animal models in cancer drug development. The Switzerland-based company, with a key financial and regulatory presence in the U.S., announced on October 7, 2026, that it is implementing New Approach Methodologies (NAMs) across its preclinical research. NAMs include cell-based assays, computational modeling, and other non-animal techniques designed to better mimic human biology.
The move matters because traditional animal testing often fails to accurately predict how experimental therapies will behave in humans, contributing to high attrition rates in clinical trials. By adopting NAMs, VERAXA aims to generate more clinically informative data earlier in the development process, potentially accelerating the path to human trials and reducing costs. The strategy supports the development of the company’s BiTAC® T-cell engagers, BiTAC-based antibody-drug conjugates, and bispecific antibody-drug conjugates for cancer treatment.
New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. In one ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, only about 10 mice were required, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. This dramatic reduction in animal use not only addresses ethical concerns but also could streamline research timelines and lower development costs.
The implications extend beyond VERAXA’s own pipeline. As regulators, including the U.S. Food and Drug Administration, increasingly embrace NAMs, companies that adopt these methods early may gain a competitive advantage in bringing therapies to market faster. VERAXA’s approach aligns with broader industry trends toward more human-relevant testing, which could ultimately lead to safer and more effective cancer treatments. For investors, the announcement signals a commitment to innovation and efficiency in drug development, potentially enhancing the company’s attractiveness in a competitive biotechnology landscape.
For more details on VERAXA Biotech’s pipeline and strategy, visit the VERAXA Biotech (NASDAQ: VRXA) investor page. The full announcement is available through Read More, and the original release can be viewed on www.newmediawire.com. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
